Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference
San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on developing proprietary molecules with strong clinical and commercial differentiation, announced today that Punit Dhillon, CEO, Emerald Bioscience will be present a corporate overview at the Benzinga Global Small Cap Virtual Conference taking place on December 8-9, 2020.
Presentation details are as follows:
Event: Benzinga Global Small Cap Virtual Conference
Presentation Date: Wednesday, December 9, 2020
Presentation Time: 12:00 – 12:15 PM ET
For more information and/or to register for the conference please visit: https://events.benzinga.com/registration-page
About Emerald Bioscience, Inc.
Emerald Bioscience Inc. is a biopharmaceutical company focused on the discovery and development of proprietary molecules with strong clinical and commercial differentiation for conditions with significant, global, unmet medical needs. With proprietary technology licensed from the University of Mississippi, the Company is developing novel ways to deliver its synthetic cannabinoid-derived molecules for specific indications with the aim of optimizing therapeutic benefit. The Company’s aim is to clinically develop multiple proprietary compounds alone or in combination with corporate partners. For more information, visit www.emeraldbio.life
CONTACT
Karam Takhar
VP Corporate Development & Investor Relations
Email: ir@emeraldbio.life
Phone: +1-949-336-3437
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development, business strategy, relocation of corporate headquarters, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Emerald may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Emerald’ most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Emerald disclaims any intent or obligation to update these forward-looking statements.
Released December 7, 2020